Mumbai: Europe's drug regulator has decided to carry out an inspection of Indian generic drugmaker Ranbaxy Laboratories Ltd's Dewas plant in India in June, amid concerns about its production processes after a spate of regulatory sanctions.
Ranbaxy, which owner Japan's Daiichi Sankyo Ltd agreed to sell it to Sun Pharmaceutical Industries Ltd for $3.2 billion on Monday.
The company's voluntary suspension at Dewas and another plant in Toansa in the northern Punjab state in February, came after a spate of sanctions against it by the US Food and Drug Administration (FDA) due to poor manufacturing processes.
Imports from Dewas had already been banned by the FDA back in 2008, after the agency found violations of drug manufacturing standards there. The FDA has also banned shipments from the three other Ranbaxy plants in India.